3 reports of this reaction
2.1% of all LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE reports
#6 most reported adverse reaction
UPPER AIRWAY COUGH SYNDROME is the #6 most commonly reported adverse reaction for LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, manufactured by Aurohealth LLC. There are 3 FDA adverse event reports linking LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE to UPPER AIRWAY COUGH SYNDROME. This represents approximately 2.1% of all 142 adverse event reports for this drug.
Patients taking LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE who experience upper airway cough syndrome should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
UPPER AIRWAY COUGH SYNDROME is a less commonly reported adverse event for LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, but still significant enough to appear in the safety profile.
In addition to upper airway cough syndrome, the following adverse reactions have been reported for LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE:
UPPER AIRWAY COUGH SYNDROME has been reported as an adverse event in 3 FDA reports for LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE. This does not prove causation, but indicates an association observed in post-market surveillance data.
UPPER AIRWAY COUGH SYNDROME accounts for approximately 2.1% of all adverse event reports for LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, making it a notable side effect.
If you experience upper airway cough syndrome while taking LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.